Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados

Topics

Temas

Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
Figuras y tablas -
Figure 1

Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
Figuras y tablas -
Figure 2

Methodological quality summary: review authors' judgements about each methodological quality item for each included study.

Ir a la figura de la revisiónAbrir en una pestaña nueva
Table 1. Operative details

Trial

Major
resections (%)

Vascular
occlusion*

Parenchymal
transection

Mean ischaemic
time (min) ‐ intervention 1**

Mean ischaemic
time (min) ‐ intervention 2**

Beck‐Shimmer 2008

28 (43.8%)

CPTC

Kelly clamp

36

35

Li 2004

not stated

CPTC

not stated

18

17

Marx 2000

19 (100%)

CPTC

not stated

26

27

Orii 2000

0 (0%)

IPTC

not stated

66

71

Stadheim 2000

23 (100%)

Afferent and efferent vessels

not stated

not stated

not stated

IPTC: intermittent portal triad clamping.
CPTC: continuous portal triad clamping.
** No significant difference between intervention and control group mean ischaemic times (P > 0.05).

Figuras y tablas -
Table 1. Operative details
Ir a la tabla de la revisión
Table 2. Outcomes reported by single trials

Outcome

Type of outcome

Intervention group 1

Intervention group 2

P value

Dopexamine versus dopamine

Blood transfusion [units]

Continuous

1.8 (2.5)

2.6 (3)

0.53

Prothrombin time [percentage of normal prothrombin activity]

Continuous

60 (13)

78 (22)

0.03*

AST [IU/L]: 1st POD

Continuous

129 (36)

137 (109)

0.83

ALT [IU/L]: 1st POD

Continuous

160 (53)

190 (155)

0.56

Prostaglandin E1 versus amrinone

Mortality

Dichotomous

0/15 (0.0%)

0/15 (0.0%)

Not applicable

Blood loss [litres]

Continuous

0.59 (0.47)

0.62 (0.41)

0.85

AST [IU/L]: 1st POD

Continuous

216 (239)

231 (152)

0.84

Prostaglandin E1 versus pentoxifylline

Liver decompensation

Dichotomous

0/13 (0.0%)

0/10 (0.0%)

Not applicable

Ulinastatin versus gantaile

Mortality

Dichotomous

0/16 (0.0%)

0/15 (0.0%)

Not applicable

Liver decompensation

Dichotomous

1/16 (6.3%)

3/15 (20.0%)

0.33

Wound infection

Dichotomous

2/16 (12.5%)

3/15 (20.0%)

0.65

Intra‐abdominal infection

Dichotomous

1/16 (6.3%)

1/15 (6.7%)

> 0.99

Hospital stay [days]

Continuous

13.3 (4)

16.4 (8.4)

0.19

Blood loss [litres]

Continuous

0.53 (0.29)

0.58 (0.31)

0.64

Sevoflurane versus propofol

Mortality

Dichotomous

1/30 (3.3%)

1/34 (2.9%)

> 0.99

Liver decompensation

Dichotomous

0/30 (0.0%)

0/34 (0.0%)

Not applicable

Intra‐abdominal infection

Dichotomous

0/30 (0.0%)

3/34 (8.8%)

0.24

Postoperative bleeding

Dichotomous

0/30 (0.0%)

2/34 (5.9%)

0.49

Bile leak

Dichotomous

1/30 (3.3%)

1/34 (2.9%)

> 0.99

ITU stay [days]

Continuous

4 (16.5)

9 (16.5)

0.23

Hospital stay [days]

Continuous

10.93 (6.8)

12.79 (6.8)

0.28

Bilirubin [mmoles/L]: peak postoperative levels

Continuous

33.67 (26.9)

44.5 (63.9)

0.37

AST [IU/L]: peak postoperative levels

Continuous

507.5 (291.8)

733.4 (636.5)

0.06

ALT [IU/L]: peak postoperative levels

Continuous

463.5 (288.0)

717.7 (497.5)

0.01*

For dichotomous outcomes, the numbers in column 'intervention group' and 'control group' denote number of patients with the outcome/total number of patients. The proportion of patients with the outcome is indicated in brackets.

For continuous outcomes, the numbers in column 'intervention group' and 'control group' denote the mean and standard deviation (in brackets) in each group.

* statistically significant
Figuras y tablas -
Table 2. Outcomes reported by single trials
Ir a la tabla de la revisión